Figure 4
Effects of BAG956 on imatinib-sensitive and imatinib-resistant BCR-ABL–expressing cells, alone and in combination with rapamycin. (A) Treatment of imatinib-resistant BCR-ABL point mutant-expressing Ba/F3 cells with BAG956 after approximately 3 days of treatment. Investigation of the effect of the combination of BAG956 and rapamycin on proliferation of Ba/F3-T315I (B), Ba/F3-F317L (C), and Ba/F3-M351T (D). Concentrations of BAG956 used: 0, 0.0275 (25% IC50), 0.055 (50% IC50), 0.11 (100% IC50), 0.22 (200% IC50), 0.44 (400% IC50) μM. Concentrations of rapamycin used: 0, 0.00 025 (25% IC50), 0.0005 (50% IC50), 0.001 (100% IC50), 0.002 (200% IC50), 0.004 (400% IC50) μM.
